Alliance Clinical Network and Atlas Clinical Research announced the completion of a strategic merger, creating a larger clinical research organization with nearly 50 years of combined industry experience. The partnership is designed to enhance clinical trial recruitment and execution capabilities while expanding the combined company’s geographic footprint across Arizona, California, Florida, Nevada, New York, Pennsylvania, and Texas.
The merger brings together complementary expertise in clinical research and strengthens therapeutic capabilities across central nervous system (CNS) disorders, internal medicine, women’s health, metabolic conditions, and dermatology. The combined organization aims to deliver improved quality, collaboration, diversity, and operational excellence for pharmaceutical sponsors and contract research organization (CRO) partners.
By integrating their site networks, therapeutic expertise, and operational best practices, the companies expect to provide greater consistency, speed, and quality in clinical trial execution. The expanded platform will also improve patient recruitment efforts and increase access to diverse patient populations across multiple disease areas.
Key benefits of the merger include:
1.Expanded therapeutic expertise across CNS, dermatology, gastroenterology, internal medicine, metabolic, pain, vaccines, and women’s health.
2.Broader geographic coverage with research sites across seven states.
3.Enhanced patient recruitment capabilities and access to diverse populations.
4.Strengthened operational excellence through aligned centers of excellence and standardized best practices.
Following the transaction, the combined company will be led by Anthony Milonas as CEO and will maintain its headquarters in Southlake, Texas. The organization will continue to receive support from healthcare-focused private equity firms Amulet Capital Partners and BPOC.
KEY QUOTES:
“This partnership provides an opportunity for us to make a greater impact on the industry and its stakeholders. We believe we are positioned to excel as we focus on predictability, consistency and transparency, while delivering performance-driven results across our expanded clinical site network.”
Anthony Milonas, CEO, Alliance Clinical Network
“This merger significantly expands our geographic footprint and creates a national platform across key clinical research markets. Together, we are better positioned to support pharmaceutical sponsors navigating increasingly complex drug development requirements while maintaining the culture, responsiveness and standards that have defined both organizations.”
Mark Scullion, CEO, Atlas Clinical Research
